[1]李 欢,王世全,李 铎.乳腺浸润性导管癌中丝氨酸蛋白酶抑制剂A1表达及对预后判断的临床价值研究[J].陕西医学杂志,2021,50(10):1292-1295.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.030]
　LI Huan,WANG Shiquan,LI Duo.Expression and prognosis value of SerPinA1 in invasive ductal carcinoma of breast[J].,2021,50(10):1292-1295.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.030]
点击复制

乳腺浸润性导管癌中丝氨酸蛋白酶抑制剂A1表达及对预后判断的临床价值研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
50
期数:
2021年10期
页码:
1292-1295
栏目:
临床病理
出版日期:
2021-10-05

文章信息/Info

Title:
Expression and prognosis value of SerPinA1 in invasive ductal carcinoma of breast
作者:
李 欢; 王世全; 李 铎
(锦州市妇婴医院乳腺科,辽宁 锦州 121000)
Author(s):
LI Huan; WANG Shiquan; LI Duo
(Department of Mammary Gland,Jinzhou Maternal and Infant Hospital,Jinzhou 121000,China)
关键词:
乳腺;  浸润性导管癌;  丝氨酸蛋白酶抑制剂A1;  临床病理特征;  预后
Keywords:
Breast;  Invasive ductal carcinoma;  SerPinA1;  Clinicopathological features;  Prognosis
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2021.10.030
文献标志码:
A
摘要:
目的:检测乳腺浸润性导管癌中丝氨酸蛋白酶抑制剂A1(SerPinA1)的表达,分析其临床意义。方法:选择93例乳腺浸润性导管癌的患者作为研究对象,留取肿瘤组织作为研究组,留取非肿瘤性乳腺组织作为对照组,应用免疫组化法检测SerPinA1蛋白的表达,分析其表达在不同临床病理特征中的差别及其表达对预后的判断价值。结果:研究组中SerPinA1的表达明显高于对照组,研究组中SerPinA1在不同肿瘤最大径、淋巴结转移、HER-2表达和组织学分级的表达中差异有统计学意义(均P<0.05)。相关分析显示SerPinA1和Ki67增殖指数呈正相关性。SerPinA1的表达与生存时间相关。结论:SerPinA1在乳腺浸润性导管癌组织中的表达升高,与肿瘤的形成和进展有关。术后检测SerPinA1的表达对判断预后有一定价值。
Abstract:
Objective:To detect the expression of serine protease inhibitor A1(SerPinA1)protein in invasive ductal carcinoma of breast,and to analyze its clinical significance.Methods:A total of 93 cases of patients with breast invasive ductal carcinoma were selected as the research objects.Tumor tissues were collected as the study group,and non-tumor breast tissues were collected as the control group.The expression of SerPinA1 protein was detected by immunohistochemistry.Expression of SerPinA1 and prognosis value were analyzed in different clinical features.Results:The expression of SerPinA1 in the study group was significantly higher than that in the control group,and the expression of SerPinA1 was significant different in tumor maximum diameter,lymph node metastasis,HER-2 expression and histological grade in the study group(all P<0.05).Positive correlation was found between SerPinA1 and Ki67.The expression of SerPinA1 was correlated with survival time.Conclusion:The expression of SerPinA1 is increased in breast invasive ductal carcinoma,which is related to the formation and progression of the tumor.Postoperative detection of SerPinA1 expression has a certain value in judging the prognosis.

参考文献/References:

[1] 陈宇斐,周小荷,李 涛,等.HUVEC-EVs通过JAK2/STAT3通路促进乳腺癌细胞增殖和迁移[J].江苏大学学报:医学版,2020,30(3):30-35.
[2] Matamala N,Maria TM,Lara B,et al.Alternative transcripts of the SERPINA1 gene in alpha-1 antitrypsin deficiency[J].J Translational Med,2015,13(1):1-11.
[3] Sidorenko DV,Nazarov VD,Lapin SV,et al.Role of molecular genetic factors in pathogenesis and diagnosis of non-alcoholic fatty liver disease(literature review and own data)[J].Med Alphabet,2020,23(5):13-19.
[4] 《乳腺癌HER2检测指南(2019版)》编写组.乳腺癌HER-2检测指南(2019版)[J].中华病理学杂志,2019,45(3):169-175.
[5] 张丽洁,李艳春,赵乔佳杰,等.TAP检测对乳腺癌患者预后判断的意义[J].山西医科大学学报,2019,50(2):112-115.
[6] Ercetin E,Richtmann S,Delgado BM,et al.Clinical significance of SERPINA1 Gene and its encoded alpha1-antitrypsin protein in NSCLC[J].Cancers(Basel),2019,11(9):1306-1307.
[7] 齐永霞,薛英杰.Snail和serpinA1表达水平在胃癌转移和浸润中的价值分析[J].中国中西医结合消化杂志,2020,28(2):9-17.
[8] 瞿 兵,陈鹏飞,李希平.胃癌组织SERPINH1基因表达水平与其病理及预后关系研究[J].国际检验医学杂志,2017,38(16):2216-2218.
[9] Enewold L,Mechanic LE,Bowman ED,et al.SERPINA1 and ELA2 polymorphisms are not associated with COPD or lung cancer[J].Anticancer Res,2012,32(9):3923-3928.
[10] Yang J,Xiong X,Wang X,et al.Identification of peptide regions of SERPINA1 and ENOSF1 and their protein expression as potential serum biomarkers for gastric cancer[J].Tumour Biol,2015,36(7):5109-5118.
[11] Vierlinger K,Mansfeld MH,Koperek O,et al.Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation[J].BMC Med Genomics,2011,6(4):30-31.
[12] Ezzikouri S,Feydi AE,Kihal L,et al.Prevalence of common HFE and SERPINA1 mutations in patients with hepatocellular carcinoma in a Moroccan population[J].Arch Med Res,2008,39(2):236-241.
[13] 乔 璐,张晓静,王 海,等.SerpinA1在大肠癌中的表达及意义[J].中国实验诊断学,2017,21(12):2053-2056.
[14] Pel MV,Os RV,Velders GA,et al.Serpina1 is a potent inhibitor of IL-8-induced hematopoietic stem cell mobilization[J].Proc Natl Acad Sci USA,2006,103(5):1469-1474.
[15] 孙 琰,李惠翔.乳腺浸润性导管癌组织ACTG2和MYH11表达及预后关系[J].中华肿瘤防治杂志,2020,27(24):1977-1983.
[16] 赵 静.乳腺浸润性导管癌组织学分级与激素受体表达的关系[J].陕西医学杂志.2012,41(12):1577-1578.
[17] 曹 威.浅谈乳腺原位癌[J].癌症进展,2020,18(24):2503-2504.
[18] Martin F,Jessica L,Suju MC.Multimodality Imaging of Common Breast Cancers[J].Contemporary Diagnostic Radiology,2020,43(26):1-6.
[19] 周 健,张 曦,何 妮,等.乳腺导管内癌MRI动态增强特征与病理分级的相关性分析[J].影像诊断与介入放射学,2020,29(6):415-420.
[20] 梁尊孝,杨 佳,王振斋,等.皮内针联合补中益气汤治疗乳腺癌根治术后癌因性疲乏疗效研究[J].陕西中医.2020,41(10):1478-1481.

相似文献/References:

[1]刘晴晴,李玉宏.三维剪切波弹性成像联合超微血流成像对乳腺结节良恶性的诊断价值[J].陕西医学杂志,2021,50(6):701.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.015]
　LIU Qingqing,LI Yuhong.Diagnostic value of 3D-SWE combined with SMI in benign and malignant breast nodules[J].,2021,50(10):701.[doi:DOI:10.3969/j.issn.1000-7377.2021.06.015]
[2]南聪慧,孟 燕.乳腺肿块型浸润性导管癌X线征象与分子受体相关性研究[J].陕西医学杂志,2022,51(8):1025.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.028]
　NAN Conghui,MENG Yan.Correlation between X-ray features and molecular receptors in breast mass-type invasive ductal carcinoma[J].,2022,51(10):1025.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.028]

更新日期/Last Update: 2021-10-08